{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:48:21Z","timestamp":1790455701352,"version":"4.1.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41584-020-00571-1","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T23:50:20Z","timestamp":1612569020000},"page":"145-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Immune cartography of macrophage activation syndrome in the COVID-19 era"],"prefix":"10.1038","volume":"17","author":[{"given":"Dennis","family":"McGonagle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athimalaipet V.","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6797-4633","authenticated-orcid":false,"given":"Charlie","family":"Bridgewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"571_CR1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","volume":"76","author":"JR Tisoncik","year":"2012","unstructured":"Tisoncik, J. R. et al. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76, 16\u201332 (2012).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"571_CR2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","volume":"10","author":"CB Crayne","year":"2019","unstructured":"Crayne, C. B., Albeituni, S., Nichols, K. E. & Cron, R. Q. The immunology of macrophage activation syndrome. Front. Immunol. 10, 119 (2019).","journal-title":"Front. Immunol."},{"key":"571_CR3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.berh.2014.03.002","volume":"28","author":"GS Schulert","year":"2014","unstructured":"Schulert, G. S. & Grom, A. A. Macrophage activation syndrome and cytokine-directed therapies. Best Pract. Res. Clin. Rheumatol. 28, 277\u2013292 (2014).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"571_CR4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","volume":"66","author":"GS Schulert","year":"2015","unstructured":"Schulert, G. S. & Grom, A. A. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu. Rev. Med. 66, 145\u2013159 (2015).","journal-title":"Annu. Rev. Med."},{"key":"571_CR5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2007.11.025","volume":"7","author":"EM Behrens","year":"2008","unstructured":"Behrens, E. M. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? Autoimmun. Rev. 7, 305\u2013308 (2008).","journal-title":"Autoimmun. Rev."},{"key":"571_CR6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/adc.2009.176610","volume":"96","author":"H Freeman","year":"2011","unstructured":"Freeman, H. & Ramanan, A. Review of haemophagocytic lymphohistiocytosis. Arch. Dis. Child. 96, 688\u2013693 (2011).","journal-title":"Arch. Dis. Child."},{"key":"571_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chom.2020.05.007","volume":"28","author":"G Dimopoulos","year":"2020","unstructured":"Dimopoulos, G. et al. Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe 28, 117\u2013123.e1 (2020).","journal-title":"Cell Host Microbe"},{"key":"571_CR8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00246-020-02391-2","volume":"41","author":"T Ramcharan","year":"2020","unstructured":"Ramcharan, T. et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital. Pediatric Cardiol. 41, 1391\u20131401 (2020).","journal-title":"Pediatric Cardiol."},{"key":"571_CR9","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","volume":"355","author":"G Suntharalingam","year":"2006","unstructured":"Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018\u20131028 (2006).","journal-title":"N. Engl. J. Med."},{"key":"571_CR10","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"571_CR11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pcl.2012.03.002","volume":"59","author":"SW Canna","year":"2012","unstructured":"Canna, S. W. & Behrens, E. M. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr. Clin. North Am. 59, 329\u2013344 (2012).","journal-title":"Pediatr. Clin. North Am."},{"key":"571_CR12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/BOR.0b013e32825a6a79","volume":"19","author":"A Kelly","year":"2007","unstructured":"Kelly, A. & Ramanan, A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 19, 477\u2013481 (2007).","journal-title":"Curr. Opin. Rheumatol."},{"key":"571_CR13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.kint.2016.11.029","volume":"92","author":"E Siddall","year":"2017","unstructured":"Siddall, E., Khatri, M. & Radhakrishnan, J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 92, 37\u201346 (2017).","journal-title":"Kidney Int."},{"key":"571_CR14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"571_CR15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMoa2021680","volume":"383","author":"LR Feldstein","year":"2020","unstructured":"Feldstein, L. R. et al. Multisystem inflammatory syndrome in US children and adolescents. N. Engl. J. Med. 383, 334\u2013346 (2020).","journal-title":"N. Engl. J. Med."},{"key":"571_CR16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.2020.10369","volume":"324","author":"E Whittaker","year":"2020","unstructured":"Whittaker, E. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 324, 259\u2013269 (2020).","journal-title":"JAMA"},{"key":"571_CR17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa2021756","volume":"383","author":"EM Dufort","year":"2020","unstructured":"Dufort, E. M. et al. Multisystem inflammatory syndrome in children in New York State. N. Engl. J. Med. 383, 347\u2013358 (2020).","journal-title":"N. Engl. J. Med."},{"key":"571_CR18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jama.1995.03520260039030","volume":"273","author":"MS Rangel-Frausto","year":"1995","unstructured":"Rangel-Frausto, M. S. et al. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 273, 117\u2013123 (1995).","journal-title":"JAMA"},{"key":"571_CR19","doi-asserted-by":"crossref","first-page":"104444","DOI":"10.1016\/j.jcv.2020.104444","volume":"129","author":"L Quartuccio","year":"2020","unstructured":"Quartuccio, L. et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian centre study on tocilizumab versus standard of care. J. Clin. Virol. 129, 104444 (2020).","journal-title":"J. Clin. Virol."},{"key":"571_CR20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(20)30243-5","volume":"8","author":"SE Fox","year":"2020","unstructured":"Fox, S. E. et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir. Med. 8, 681\u2013686 (2020).","journal-title":"Lancet Respir. Med."},{"key":"571_CR21","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(10)61345-1","volume":"376","author":"J-I Henter","year":"2010","unstructured":"Henter, J.-I., Palmkvist-Kaijser, K., Holzgraefe, B., Bryceson, Y. T. & Palm\u00e9r, K. Cytotoxic therapy for severe swine flu A\/H1N1. Lancet 376, 2116 (2010).","journal-title":"Lancet"},{"key":"571_CR22","first-page":"1180","volume":"103","author":"J Henter","year":"2006","unstructured":"Henter, J. Can cytostatics be effective in severe avian influenza? The disease picture has similarities with hemophagocytic lymphohistiocytosis. Lakartidningen 103, 1180 (2006).","journal-title":"Lakartidningen"},{"key":"571_CR23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0140-6736(06)68232-9","volume":"367","author":"J-I Henter","year":"2006","unstructured":"Henter, J.-I., Chow, C.-B., Leung, C.-W. & Lau, Y.-L. Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet 367, 870\u2013873 (2006).","journal-title":"Lancet"},{"key":"571_CR24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","volume":"377","author":"H Feldmann","year":"2011","unstructured":"Feldmann, H. & Geisbert, T. W. Ebola haemorrhagic fever. Lancet 377, 849\u2013862 (2011).","journal-title":"Lancet"},{"key":"571_CR25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.150108","volume":"42","author":"RQ Cron","year":"2015","unstructured":"Cron, R. Q., Behrens, E. M., Shakoory, B., Ramanan, A. V. & Chatham, W. W. Does viral hemorrhagic fever represent reactive hemophagocytic syndrome? J. Rheumatol. 42, 1078\u20131080 (2015).","journal-title":"J. Rheumatol."},{"key":"571_CR26","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1128\/JVI.70.4.2208-2214.1996","volume":"70","author":"H Feldmann","year":"1996","unstructured":"Feldmann, H. et al. Filovirus-induced endothelial leakage triggered by infected monocytes\/macrophages. J. Virol. 70, 2208\u20132214 (1996).","journal-title":"J. Virol."},{"key":"571_CR27","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1073\/pnas.1321748111","volume":"111","author":"Z Wang","year":"2014","unstructured":"Wang, Z. et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc. Natl Acad. Sci. USA 111, 769\u2013774 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"571_CR28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/PCC.0b013e3181a1ae08","volume":"10","author":"L Castillo","year":"2009","unstructured":"Castillo, L. & Carcillo, J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis\/systemic inflammatory response syndrome\/multiorgan dysfunction syndrome\/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr. Crit. Care Med. 10, 387\u2013392 (2009).","journal-title":"Pediatr. Crit. Care Med."},{"key":"571_CR29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/annrheumdis-2017-211687","volume":"77","author":"V Sch\u00f6nau","year":"2018","unstructured":"Sch\u00f6nau, V. et al. The value of 18F-FDG-PET\/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study. Ann. Rheum. Dis. 77, 70\u201377 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"571_CR30","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00296-009-1137-7","volume":"30","author":"J-Y Choe","year":"2010","unstructured":"Choe, J.-Y., Chung, D. S., Park, S.-H., Kwon, H.-H. & Kim, S.-K. Clinical significance of 18 F-fluoro-dexoxyglucose positron emission tomography in patients with adult-onset Still\u2019s disease: report of two cases and review of literatures. Rheumatol. Int. 30, 1673\u20131676 (2010).","journal-title":"Rheumatol. Int."},{"key":"571_CR31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/82763","volume":"1","author":"P Chomarat","year":"2000","unstructured":"Chomarat, P., Banchereau, J., Davoust, J. & Palucka, A. K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1, 510\u2013514 (2000).","journal-title":"Nat. Immunol."},{"key":"571_CR32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1471-4906(02)02260-3","volume":"23","author":"JA Hamilton","year":"2002","unstructured":"Hamilton, J. A. GM-CSF in inflammation and autoimmunity. Trends Immunol. 23, 403\u2013408 (2002).","journal-title":"Trends Immunol."},{"key":"571_CR33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2741\/2692","volume":"13","author":"FO Martinez","year":"2008","unstructured":"Martinez, F. O., Sica, A., Mantovani, A. & Locati, M. Macrophage activation and polarization. Front. Biosci. 13, 453 (2008).","journal-title":"Front. Biosci."},{"key":"571_CR34","volume":"9","author":"MR Fernando","year":"2014","unstructured":"Fernando, M. R., Reyes, J. L., Iannuzzi, J., Leung, G. & McKay, D. M. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS ONE 9, e94188 (2014).","journal-title":"PLoS ONE"},{"key":"571_CR35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan, M. B., Hildeman, D., Kappler, J. & Marrack, P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104, 735\u2013743 (2004).","journal-title":"Blood"},{"key":"571_CR36","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","volume":"121","author":"EM Behrens","year":"2011","unstructured":"Behrens, E. M. et al. Repeated TLR9 stimulation results in macrophage activation syndrome\u2013like disease in mice. J. Clin. Invest. 121, 2264\u20132277 (2011).","journal-title":"J. Clin. Invest."},{"key":"571_CR37","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.immuni.2013.06.019","volume":"39","author":"H Ohyagi","year":"2013","unstructured":"Ohyagi, H. et al. Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. Immunity 39, 584\u2013598 (2013).","journal-title":"Immunity"},{"key":"571_CR38","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/art.24883","volume":"60","author":"A Parodi","year":"2009","unstructured":"Parodi, A. et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 60, 3388\u20133399 (2009).","journal-title":"Arthritis Rheum."},{"key":"571_CR39","doi-asserted-by":"crossref","first-page":"108255","DOI":"10.1016\/j.clim.2019.108255","volume":"208","author":"M Usami","year":"2019","unstructured":"Usami, M. et al. Extensive serum biomarker analysis in patients with macrophage activation syndrome associated with systemic lupus erythematosus. Clin. Immunol. 208, 108255 (2019).","journal-title":"Clin. Immunol."},{"key":"571_CR40","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jaci.2014.11.030","volume":"135","author":"B Tesi","year":"2015","unstructured":"Tesi, B. et al. Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-\u03b3 receptor deficiency. J. Allergy Clin. Immunol. 135, 1638\u20131641 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"571_CR41","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/art.37958","volume":"65","author":"SW Canna","year":"2013","unstructured":"Canna, S. W. et al. Interferon-\u03b3 mediates anemia but is dispensable for fulminant Toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum. 65, 1764\u20131775 (2013).","journal-title":"Arthritis Rheum."},{"key":"571_CR42","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2009-11-255174","volume":"116","author":"JD Milner","year":"2010","unstructured":"Milner, J. D. et al. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood 116, 2476\u20132483 (2010).","journal-title":"Blood"},{"key":"571_CR43","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1189\/jlb.0412214","volume":"92","author":"IG Luzina","year":"2012","unstructured":"Luzina, I. G. et al. Regulation of inflammation by interleukin-4: a review of \u201calternatives\u201d. J. Leukoc. Biol. 92, 753\u2013764 (2012).","journal-title":"J. Leukoc. Biol."},{"key":"571_CR44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0609.2004.00318.x","volume":"74","author":"DJ Schaer","year":"2005","unstructured":"Schaer, D. J. et al. Soluble hemoglobin\u2013haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur. J. Haematol. 74, 6\u201310 (2005).","journal-title":"Eur. J. Haematol."},{"key":"571_CR45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom, A. A., Horne, A. & De Benedetti, F. Macrophage activation syndrome in the era of biologic therapy. Nat. Rev. Rheumatol. 12, 259\u2013268 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"571_CR46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.0105-2896.2010.00890.x","volume":"235","author":"JP Schmid","year":"2010","unstructured":"Schmid, J. P. et al. Inherited defects in lymphocyte cytotoxic activity. Immunol. Rev. 235, 10\u201323 (2010).","journal-title":"Immunol. Rev."},{"key":"571_CR47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.20140964","volume":"212","author":"MR Jenkins","year":"2015","unstructured":"Jenkins, M. R. et al. Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J. Exp. Med. 212, 307\u2013317 (2015).","journal-title":"J. Exp. Med."},{"key":"571_CR48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood-2017-11-814244","volume":"132","author":"IK Chinn","year":"2018","unstructured":"Chinn, I. K. et al. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood 132, 89\u2013100 (2018).","journal-title":"Blood"},{"key":"571_CR49","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/humu.20274","volume":"27","author":"UZ Stadt","year":"2006","unstructured":"Stadt, U. Z. et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum. Mutat. 27, 62\u201368 (2006).","journal-title":"Hum. Mutat."},{"key":"571_CR50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fped.2016.00047","volume":"4","author":"E Ishii","year":"2016","unstructured":"Ishii, E. Hemophagocytic lymphohistiocytosis in children: pathogenesis and treatment. Front. Pediatr. 4, 47 (2016).","journal-title":"Front. Pediatr."},{"key":"571_CR51","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2014-06-582791","volume":"124","author":"CE Allen","year":"2014","unstructured":"Allen, C. E. & McClain, K. L. fHLH: becoming a blended family. Blood 124, 1210\u20131211 (2014).","journal-title":"Blood"},{"key":"571_CR52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/asheducation-2015.1.177","volume":"2015","author":"CE Allen","year":"2015","unstructured":"Allen, C. E. & McClain, K. L. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology 2015, 177\u2013182 (2015).","journal-title":"Hematology"},{"key":"571_CR53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41435-020-0098-4","volume":"21","author":"GS Schulert","year":"2020","unstructured":"Schulert, G. S. & Cron, R. Q. The genetics of macrophage activation syndrome. Genes Immun. 21, 169\u2013181 (2020).","journal-title":"Genes Immun."},{"key":"571_CR54","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1182\/blood-2011-07-370148","volume":"118","author":"K Zhang","year":"2011","unstructured":"Zhang, K. et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 118, 5794\u20135798 (2011).","journal-title":"Blood"},{"key":"571_CR55","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/rheumatology\/kep418","volume":"49","author":"SJ Vastert","year":"2010","unstructured":"Vastert, S. J. et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology 49, 441\u2013449 (2010).","journal-title":"Rheumatology"},{"key":"571_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1546-0096-12-1","volume":"12","author":"C Bracaglia","year":"2014","unstructured":"Bracaglia, C. et al. Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA). Pediatric Rheumatol. 12, 1\u20132 (2014).","journal-title":"Pediatric Rheumatol."},{"key":"571_CR57","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/art.38793","volume":"66","author":"KM Kaufman","year":"2014","unstructured":"Kaufman, K. M. et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 66, 3486\u20133495 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"571_CR58","first-page":"1133","volume":"34","author":"EM Behrens","year":"2007","unstructured":"Behrens, E. M., Beukelman, T., Paessler, M. & Cron, R. Q. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol. 34, 1133\u20131138 (2007).","journal-title":"J. Rheumatol."},{"key":"571_CR59","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1309\/AJCP4ZDKJ4ICOUAT","volume":"139","author":"FG Rosado","year":"2013","unstructured":"Rosado, F. G. & Kim, A. S. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am. J. Clin. Pathol. 139, 713\u2013727 (2013).","journal-title":"Am. J. Clin. Pathol."},{"key":"571_CR60","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","volume":"105","author":"AD Billiau","year":"2005","unstructured":"Billiau, A. D., Roskams, T., Van Damme-Lombaerts, R., Matthys, P. & Wouters, C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-\u03b3-producing lymphocytes and IL-6-and TNF-\u03b1-producing macrophages. Blood 105, 1648\u20131651 (2005).","journal-title":"Blood"},{"key":"571_CR61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/archdischild-2016-310772","volume":"102","author":"ES Sen","year":"2017","unstructured":"Sen, E. S., Steward, C. G. & Ramanan, A. V. Diagnosing haemophagocytic syndrome. Arch. Dis. Child. 102, 279\u2013284 (2017).","journal-title":"Arch. Dis. Child."},{"key":"571_CR62","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"A Ravelli","year":"2016","unstructured":"Ravelli, A. et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann. Rheum. Dis. 75, 481\u2013489 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"571_CR63","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479\u20131486 (2005).","journal-title":"J. Exp. Med."},{"key":"571_CR64","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","volume":"59","author":"S Yasin","year":"2020","unstructured":"Yasin, S. et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology 59, 361\u2013366 (2020).","journal-title":"Rheumatology"},{"key":"571_CR65","doi-asserted-by":"crossref","first-page":"15970","DOI":"10.1073\/pnas.1520779112","volume":"112","author":"MJ Ombrello","year":"2015","unstructured":"Ombrello, M. J. et al. HLA-DRB1* 11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc. Natl Acad. Sci. USA 112, 15970\u201315975 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"571_CR66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/annrheumdis-2019-215239","volume":"79","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. Both HLA class I and II regions identified as genome-wide significant susceptibility loci for adult-onset Still\u2019s disease in Chinese individuals. Ann. Rheum. Dis. 79, 161\u2013163 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"571_CR67","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/annrheumdis-2016-210324","volume":"76","author":"MJ Ombrello","year":"2017","unstructured":"Ombrello, M. J. et al. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann. Rheum. Dis. 76, 906\u2013913 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"571_CR68","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41584-020-0377-5","volume":"16","author":"S Savic","year":"2020","unstructured":"Savic, S., Caseley, E. A. & McDermott, M. F. Moving towards a systems-based classification of innate immune-mediated diseases. Nat. Rev. Rheumatol. 16, 222\u2013237 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"571_CR69","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","volume":"71","author":"A Martini","year":"2012","unstructured":"Martini, A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann. Rheum. Dis. 71, 1437\u20131439 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"571_CR70","doi-asserted-by":"crossref","first-page":"15785","DOI":"10.1073\/pnas.1521837113","volume":"112","author":"PA Nigrovic","year":"2015","unstructured":"Nigrovic, P. A. Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis. Proc. Natl Acad. Sci. USA 112, 15785\u201315786 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"571_CR71","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-017-2993-y","volume":"96","author":"M Lin","year":"2017","unstructured":"Lin, M. et al. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann. Hematol. 96, 1241\u20131251 (2017).","journal-title":"Ann. Hematol."},{"key":"571_CR72","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"issue":"suppl. 15","key":"571_CR73","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1200\/JCO.2020.38.15_suppl.8057","volume":"38","author":"S Ahmed","year":"2020","unstructured":"Ahmed, S. et al. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). J. Clin. Oncol. 38 (suppl. 15), 8057 (2020).","journal-title":"J. Clin. Oncol."},{"key":"571_CR74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030297","volume":"3","author":"D McGonagle","year":"2006","unstructured":"McGonagle, D. & McDermott, M. F. A proposed classification of the immunological diseases. PLoS Med. 3, e297 (2006).","journal-title":"PLoS Med."},{"key":"571_CR75","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrrheum.2013.101","volume":"9","author":"G Grateau","year":"2013","unstructured":"Grateau, G. et al. How should we approach classification of autoinflammatory diseases? Nat. Rev. Rheumatol. 9, 624 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"571_CR76","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.13462","volume":"170","author":"K Lehmberg","year":"2015","unstructured":"Lehmberg, K. et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br. J. Haematol. 170, 539\u2013549 (2015).","journal-title":"Br. J. Haematol."},{"key":"571_CR77","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.40417","volume":"70","author":"RE Borgia","year":"2018","unstructured":"Borgia, R. E., Gerstein, M., Levy, D. M., Silverman, E. D. & Hiraki, L. T. Features, treatment, and outcomes of macrophage activation syndrome in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 70, 616\u2013624 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"571_CR78","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","volume":"123","author":"N Daver","year":"2017","unstructured":"Daver, N. et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 123, 3229\u20133240 (2017).","journal-title":"Cancer"},{"key":"571_CR79","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(09)70140-8","volume":"10","author":"K Shimada","year":"2009","unstructured":"Shimada, K., Kinoshita, T., Naoe, T. & Nakamura, S. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol. 10, 895\u2013902 (2009).","journal-title":"Lancet Oncol."},{"key":"571_CR80","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/bloodadvances.2017005561","volume":"1","author":"EJ Vick","year":"2017","unstructured":"Vick, E. J., Patel, K., Prouet, P. & Martin, M. G. Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy. Blood Adv. 1, 779\u2013791 (2017).","journal-title":"Blood Adv."},{"key":"571_CR81","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1349-7006.2007.00549.x","volume":"98","author":"HC Chuang","year":"2007","unstructured":"Chuang, H. C., Lay, J. D., Hsieh, W. C. & Su, I. J. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein\u2013Barr virus-associated T-cell lymphoma: nuclear factor-\u03baB pathway as a potential therapeutic target. Cancer Sci. 98, 1281\u20131287 (2007).","journal-title":"Cancer Sci."},{"key":"571_CR82","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/590152","volume":"47","author":"F M\u00e1nard","year":"2008","unstructured":"M\u00e1nard, F. et al. Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin. Infect. Dis. 47, 531\u2013534 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"571_CR83","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"RD Sandler","year":"2020","unstructured":"Sandler, R. D. et al. Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party (ADWP) and transplant complications working party (TCWP). Front. Immunol. 11, 524 (2020).","journal-title":"Front. Immunol."},{"key":"571_CR84","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41409-019-0637-7","volume":"55","author":"RD Sandler","year":"2019","unstructured":"Sandler, R. D. et al. Haemophagocytic lymphohistiocytosis (HLH) following allogeneic haematopoietic stem cell transplantation (HSCT) \u2014 time to reappraise with modern diagnostic and treatment strategies? Bone Marrow Transplant. 55, 307\u2013316 (2019).","journal-title":"Bone Marrow Transplant."},{"key":"571_CR85","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/art.33496","volume":"64","author":"R Strippoli","year":"2012","unstructured":"Strippoli, R. et al. 2012. Amplification of the response to Toll\u2010like receptor ligands by prolonged exposure to interleukin\u20106 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum.64, 1680\u20131688 (2012).","journal-title":"Arthritis Rheum."},{"key":"571_CR86","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey, D. T. et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154\u20135157 (2013).","journal-title":"Blood"},{"key":"571_CR87","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fphar.2020.00557","volume":"11","author":"A Ceschi","year":"2020","unstructured":"Ceschi, A., Noseda, R., Palin, K. & Verhamme, K. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front. Pharmacol. 11, 557\u2013557 (2020).","journal-title":"Front. Pharmacol."},{"key":"571_CR88","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","volume":"19","author":"D McGonagle","year":"2020","unstructured":"McGonagle, D., Sharif, K., O\u2019Regan, A. & Bridgewood, C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun. Rev. 19, 102537 (2020).","journal-title":"Autoimmun. Rev."},{"key":"571_CR89","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","volume":"76","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia, C. et al. Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 76, 166\u2013172 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"571_CR90","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"571_CR91","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1073\/pnas.90.21.10188","volume":"90","author":"RA Seder","year":"1993","unstructured":"Seder, R. A., Gazzinelli, R., Sher, A. & Paul, W. E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc. Natl Acad. Sci. USA 90, 10188\u201310192 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"571_CR92","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli, F. et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N. Engl. J. Med. 382, 1811\u20131822 (2020).","journal-title":"N. Engl. J. Med."},{"key":"571_CR93","first-page":"178","volume":"78","author":"F De Benedetti","year":"2019","unstructured":"De Benedetti, F. et al. OP0204 EMAPALUMAB, an interferon gamma (IFN-Y)-BLOCKING monoclonal antibody, in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (SJIA). Ann. Rheum. Dis.78, 178 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"571_CR94","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/art.41076","volume":"72","author":"TN Burn","year":"2020","unstructured":"Burn, T. N. et al. Genetic deficiency of interferon-\u03b3 reveals interferon-\u03b3-independent manifestations of murine hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 72, 335\u2013347 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"571_CR95","first-page":"840","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay, C. et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann. Rheum. Dis. 77, 840\u2013847 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"571_CR96","first-page":"289","volume":"4","author":"C Dinarello","year":"2013","unstructured":"Dinarello, C., Novick, D., Kim, S. & Kaplanski, G. Interleukin-18 and IL-18 binding protein. Front. Immunol. 4, 289 (2013).","journal-title":"Front. Immunol."},{"key":"571_CR97","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","volume":"160","author":"M Shimizu","year":"2015","unstructured":"Shimizu, M. et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin. Immunol. 160, 277\u2013281 (2015).","journal-title":"Clin. Immunol."},{"key":"571_CR98","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss, E. S. et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood 131, 1442\u20131455 (2018).","journal-title":"Blood"},{"key":"571_CR99","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","volume":"169","author":"N Inoue","year":"2016","unstructured":"Inoue, N. et al. Cytokine profile in adult-onset Still\u2019s disease: comparison with systemic juvenile idiopathic arthritis. Clin. Immunol. 169, 8\u201313 (2016).","journal-title":"Clin. Immunol."},{"key":"571_CR100","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ng.3066","volume":"46","author":"N Romberg","year":"2014","unstructured":"Romberg, N. et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat. Genet. 46, 1135\u20131139 (2014).","journal-title":"Nat. Genet."},{"key":"571_CR101","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.ccc044","author":"LH Calabrese","year":"2020","unstructured":"Calabrese, L. H. & Calabrese, C. Cytokine release syndrome and the prospects for immunotherapy with COVID-19. Part 2: the role of interleukin 1. Cleve. Clin. J. Med. https:\/\/doi.org\/10.3949\/ccjm.87a.ccc044 (2020).","journal-title":"Cleve. Clin. J. Med."},{"key":"571_CR102","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","volume":"2","author":"G Cavalli","year":"2020","unstructured":"Cavalli, G. et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2, e325\u2013e331 (2020).","journal-title":"Lancet Rheumatol."},{"key":"571_CR103","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.05.002","volume":"146","author":"E Pontali","year":"2020","unstructured":"Pontali, E. et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J. Allergy Clin. Immunol. 146, 213\u2013215 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"571_CR104","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","volume":"37","author":"HE S\u00f6nmez","year":"2018","unstructured":"S\u00f6nmez, H. E., Demir, S., Bilginer, Y. & \u00d6zen, S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin. Rheumatol. 37, 3329\u20133335 (2018).","journal-title":"Clin. Rheumatol."},{"key":"571_CR105","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e, P. et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133, 2465\u20132477 (2019).","journal-title":"Blood"},{"key":"571_CR106","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.150108","volume":"42","author":"RQ Cron","year":"2015","unstructured":"Cron, R. Q., Behrens, E. M., Shakoory, B., Ramanan, A. V. & Chatham, W. W. Does viral hemorrhagic fever represent reactive hemophagocytic syndrome? J. Rheumatol. 42, 1078\u20131080 (2015).","journal-title":"J. Rheumatol."},{"key":"571_CR107","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","volume":"68","author":"AA Grom","year":"2016","unstructured":"Grom, A. A. et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol. 68, 218\u2013228 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"571_CR108","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.4049\/jimmunol.155.9.4347","volume":"155","author":"C Hunter","year":"1995","unstructured":"Hunter, C., Chizzonite, R. & Remington, J. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J. Immunol. 155, 4347\u20134354 (1995).","journal-title":"J. Immunol."},{"key":"571_CR109","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/eji.1830260736","volume":"26","author":"MJ Micallef","year":"1996","unstructured":"Micallef, M. J. et al. Interferon-\u03b3-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-\u03b3 production. Eur. J. Immunol. 26, 1647\u20131651 (1996).","journal-title":"Eur. J. Immunol."},{"key":"571_CR110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2020006216","volume":"136","author":"MJ Frigault","year":"2020","unstructured":"Frigault, M. J. et al. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood 136, 137\u2013139 (2020).","journal-title":"Blood"},{"key":"571_CR111","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385\u20132395 (2012).","journal-title":"N. Engl. J. Med."},{"key":"571_CR112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/s10165-010-0348-9","volume":"21","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi, M., Takahashi, Y., Yamashita, H., Kaneko, H. & Mimori, A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome. Mod. Rheumatol. 21, 92\u201396 (2011).","journal-title":"Mod. Rheumatol."},{"key":"571_CR113","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.140288","volume":"42","author":"S Yokota","year":"2015","unstructured":"Yokota, S. et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J. Rheumatol. 42, 712\u2013722 (2015).","journal-title":"J. Rheumatol."},{"key":"571_CR114","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"571_CR115","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","volume":"6","author":"A Ahmed","year":"2019","unstructured":"Ahmed, A. et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 6, e630\u2013e637 (2019).","journal-title":"Lancet Haematol."},{"key":"571_CR116","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001246","volume":"6","author":"M Kacar","year":"2020","unstructured":"Kacar, M. et al. Mixed results with baricitinib in biological-resistant adult-onset Still\u2019s disease and undifferentiated systemic autoinflammatory disease. RMD Open 6, e001246 (2020).","journal-title":"RMD Open"},{"key":"571_CR117","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","volume":"79","author":"Q Hu","year":"2020","unstructured":"Hu, Q. et al. Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a single centre in China. Ann. Rheum. Dis. 79, 842\u2013844 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"571_CR118","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033 (2020).","journal-title":"Lancet"},{"key":"571_CR119","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/annrheumdis-2020-218048","volume":"79","author":"P Ruscitti","year":"2020","unstructured":"Ruscitti, P. et al. Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence\u2013radiological differences. Ann. Rheum. Dis. 79, 1152\u20131155 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"571_CR120","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","volume":"19","author":"D McGonagle","year":"2020","unstructured":"McGonagle, D., Sharif, K., O\u2019Regan, A. & Bridgewood, C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun. Rev. 19, 102537 (2020).","journal-title":"Autoimmun. Rev."},{"key":"571_CR121","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet, L. et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 66, 2613\u20132620 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"571_CR122","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","volume":"180","author":"P Sinha","year":"2020","unstructured":"Sinha, P., Matthay, M. A. & Calfee, C. S. Is a \u201cCytokine Storm\u201d relevant to COVID-19? JAMA Intern. Med. 180, 1152\u20131154 (2020).","journal-title":"JAMA Intern. Med."},{"key":"571_CR123","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507\u2013513 (2020).","journal-title":"Lancet"},{"key":"571_CR124","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"571_CR125","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S2665-9913(20)30121-1","volume":"2","author":"D McGonagle","year":"2020","unstructured":"McGonagle, D., O\u2019Donnell, J. S., Sharif, K., Emery, P. & Bridgewood, C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2, e437\u2013e445 (2020).","journal-title":"Lancet Rheumatol."},{"key":"571_CR126","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2213-2600(20)30244-7","volume":"8","author":"D McGonagle","year":"2020","unstructured":"McGonagle, D., Plein, S., O\u2019Donnell, J. S., Sharif, K. & Bridgewood, C. Increased cardiovascular mortality in African Americans with COVID-19. Lancet Respir. Med. 8, 649\u2013651 (2020).","journal-title":"Lancet Respir. Med."},{"key":"571_CR127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","author":"P Horby","year":"2020","unstructured":"Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19 \u2014 preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2021436 (2020).","journal-title":"N. Engl. J. Med."},{"key":"571_CR128","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/infdis\/jiv550","volume":"213","author":"GS Schulert","year":"2016","unstructured":"Schulert, G. S. et al. Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. J. Infect. Dis. 213, 1180\u20131188 (2016).","journal-title":"J. Infect. Dis."},{"key":"571_CR129","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718\u2013724 (2020).","journal-title":"Science"},{"key":"571_CR130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2020.13719","volume":"324","author":"CI van der Made","year":"2020","unstructured":"van der Made, C. I. et al. Presence of genetic variants among young men with severe COVID-19. JAMA 324, 1\u201311 (2020).","journal-title":"JAMA"},{"key":"571_CR131","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.18.157933","author":"RV Blair","year":"2020","unstructured":"Blair, R. V. et al. ARDS and cytokine storm in SARS-CoV-2 infected Caribbean Vervets. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.06.18.157933 (2020).","journal-title":"bioRxiv"},{"key":"571_CR132","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S1473-3099(20)30651-4","volume":"20","author":"L Jiang","year":"2020","unstructured":"Jiang, L. et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect. Dis. 20, e276\u2013e288 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"571_CR133","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S2352-4642(20)30215-7","volume":"4","author":"P Davies","year":"2020","unstructured":"Davies, P. et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc. Health 4, 669\u2013677 (2020).","journal-title":"Lancet Child Adolesc. Health"},{"key":"571_CR134","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMe2023158","volume":"383","author":"M Levin","year":"2020","unstructured":"Levin, M. Childhood multisystem inflammatory syndrome \u2014 a new challenge in the pandemic. N. Engl. J .Med. 383, 393\u2013395 (2020).","journal-title":"N. Engl. J .Med."},{"key":"571_CR135","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jama.2020.10370","volume":"324","author":"BW McCrindle","year":"2020","unstructured":"McCrindle, B. W. & Manlhiot, C. SARS-CoV-2-related inflammatory multisystem syndrome in children: different or shared etiology and pathophysiology as Kawasaki disease? JAMA 324, 246\u2013248 (2020).","journal-title":"JAMA"},{"key":"571_CR136","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200361","author":"V Natoli","year":"2020","unstructured":"Natoli, V., Rosina, S. & Ravelli, A. Is macrophage activation syndrome in Kawasaki disease underrecognized? J. Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.200361 (2020).","journal-title":"J. Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-00571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-00571-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-00571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T09:46:54Z","timestamp":1697795214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-00571-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-00571-1","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"23 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}